Status epilepticus: An update

Current Neurology and Neuroscience Reports

Volumn 13, Issue 7, 2013, Pages

  Varelas, Panayiotis N ^a,b   Spanaki, Marianna V ^a,c   Mirski, Marek A ^d  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Antiepileptic drugs; Definition; Seizures; Status epilepticus; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CIPROFLOXACIN; COCAINE; DESFLURANE; DIAZEPAM; ETIRACETAM; FOSPHENYTOIN SODIUM; GABAPENTIN; HARKOSERIDE; ISOFLURANE; KETAMINE; LITHIUM; LORAZEPAM; MAGNESIUM; MIDAZOLAM; PENTOBARBITAL; PHENOBARBITAL; PHENYTOIN; PLACEBO; PREGABALIN; PROPOFOL; PYRIDOXINE; THEOPHYLLINE; THIOPENTAL; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN;

ACUTE INTERMITTENT PORPHYRIA; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN HYPOXIA; BRAIN INJURY; CEREBROVASCULAR ACCIDENT; CONTINUOUS INFUSION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; HUMAN; HYPOTENSION; INCIDENCE; KETOGENIC DIET; LOADING DRUG DOSE; METABOLIC DISORDER; MORBIDITY; MORTALITY; NEUROSURGERY; PATHOGENESIS; PATIENT CARE; PATIENT MONITORING; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RISK ASSESSMENT; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION; CLINICAL PROTOCOL; PATHOPHYSIOLOGY; STATUS EPILEPTICUS;

ANTICONVULSANTS; CLINICAL PROTOCOLS; HUMANS; STATUS EPILEPTICUS;

EID: 84877660937     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-013-0357-0     Document Type: Article

References (88)

1. Varelas PN, Mirski MA. Status epilepticus. Curr Neurol Neurosci Rep. 2009;9:469-76.
2. Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17:348-55.
3. •• Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17:3-23. These are latest guidelines from a large writing group representing the Neurocritical Care Society and using the GRADE system.
4. Gastaut H. Classification of status epilepticus. Adv Neurol. 1983;34:15-35.
5. Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on status epilepticus. JAMA. 1993;270:854-9.
6. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia. 1999;40:120-2.
7. Jenssen S, Gracely EJ, Sperling MR. How long do most seizures last? A systematic comparison of seizures recorded in the epilepsy monitoring unit. Epilepsia. 2006;47:1499-503.
8. Goodkin HP, Kapur J. Responsiveness of status epilepticus to treatment with diazepan decreases rapidly as seizure duration increases. Epilepsy Curr. 2003;3:11-2.
9. Lowenstein DH. The management of refractory status epilepticus: an update. Epilepsia. 2006;47 Suppl 1:35-40.
10. Shorvon S. What is nonconvulsive status epilepticus, and what are its subtypes? Epilepsia. 2007;48 Suppl 8:35-8.
11. Kaplan PW. Assessing the outcomes in patients with nonconvulsive status epilepticus: nonconvulsive status epilepticus is underdiagnosed, potentially overtreated, and confounded by comorbidity. J Clin Neurophysiol. 1999;16:341-52.
12. Walker MC. Diagnosis and treatment of nonconvulsive status epilepticus. CNS Drugs. 2001;15:931-9.
13. Kaplan PW. EEG criteria for nonconvulsive status epilepticus. Epilepsia. 2007;48 Suppl 8:39-41.
14. Sutter R, Kaplan PW. Electroencephalographic criteria for nonconvulsive status epilepticus: synopsis and comprehensive survey. Epilepsia. 2012;53 Suppl 3:1-51.
15. • Trinka E, Hofler J, Zerbs A. Causes of status epilepticus. Epilepsia. 2012;53 Suppl 4:127-38. This is a comprehensive review of the causes of SE.
16. Hauser WA. Status epilepticus: epidemiologic considerations. Neurology. 1990;40:9-13.
17. DeLorenzo RJ, Hauser WA, Towne AR, et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46:1029-35.
18. Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339:792-8.
19. Jordan KG. Nonconvulsive status epilepticus in acute brain injury. J Clin Neurophysiol. 1999;16:332-40. discussion 353.
20. Carrera E, Michel P, Despland PA, et al. Continuous assessment of electrical epileptic activity in acute stroke. Neurology. 2006;67:99-104.
21. Towne AR, Waterhouse EJ, Boggs JG, et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology. 2000;54:340-5.
22. Claassen J, Jette N, Chum F, et al. Electrographic seizures and periodic discharges after intracerebral hemorrhage. Neurology. 2007;69:1356-65.
23. Claassen J, Peery S, Kreiter KT, et al. Predictors and clinical impact of epilepsy after subarachnoid hemorrhage. Neurology. 2003;60:208-14.
24. Cocito L, Audenino D, Primavera A. Altered mental state and nonconvulsive status epilepticus in patients with cancer. Arch Neurol. 2001;58:1310.
25. Vespa PM, Nuwer MR, Nenov V, et al. Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring. J Neurosurg. 1999;91:750-60.
26. Mayer SA, Claassen J, Lokin J, Mendelsohn F, Dennis LJ, Fitzsimmons BF. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol. 2002;59:205-10.
27. Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry. 2005;76:534-9.
28. • Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51:251-6. This is a prospective study of RSE outcomes.
29. Wijdicks EF, Sharbrough FW. New-onset seizures in critically ill patients. Neurology. 1993;43:1042-4.
30. Bleck TP, Smith MC, Pierre-Louis SJ, Jares JJ, Murray J, Hansen CA. Neurologic complications of critical medical illnesses. Crit Care Med. 1993;21:98-103.
31. Drislane FW, Lopez MR, Blum AS, Schomer DL. Detection and treatment of refractory status epilepticus in the intensive care unit. J Clin Neurophysiol. 2008;25:181-6.
32. Bauer G, Trinka E. Nonconvulsive status epilepticus and coma. Epilepsia. 2010;51:177-90.
33. Tan RY, Neligan A, Shorvon SD. The uncommon causes of status epilepticus: a systematic review. Epilepsy Res. 2010;91:111-22.
34. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med. 1998;338:970-6.
35. Millikan D, Rice B, Silbergleit R. Emergency treatment of status epilepticus: current thinking. Emerg Med Clin North Am. 2009;27:101-1.
36. Fountain NB. Status epilepticus: risk factors and complications. Epilepsia. 2000;41 Suppl 2:S23-30.
37. Aminoff MJ, Simon RP. Status epilepticus. Causes, clinical features and consequences in 98 patients. Am J Med. 1980;69:657-66.
38. Loscher W. Mechanisms of drug resistance in status epilepticus. Epilepsia. 2007;48 Suppl 8:74-7.
39. Bankstahl JP, Loscher W. Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res. 2008;82:70-85.
40. DeLorenzo RJ, Waterhouse EJ, Towne AR, et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia. 1998;39:833-40.
41. Brenner RP. Is it status? Epilepsia. 2002;43 Suppl 3:103-13.
42. Kaplan PW. The EEG of status epilepticus. J Clin Neurophysiol. 2006;23:221-9.
43. Pedersen GL, Rasmussen SB, Gyllenborg J, Benedek K, Lauritzen M. Prognostic value of periodic electroencephalographic discharges for neurological patients with profound disturbances of consciousness. Clin Neurophysiol. 2013;124:44-51.
44. • Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69:892-900. This is an important article describing a new seizure entity with important implications.
45. Irani SR, Vincent A, Schott JM. Autoimmune encephalitis. BMJ. 2011;342:d1918.
46. Varelas PN, Spanaki MV. Management of status epilepticus and critical care seizures. In: Varelas PN, editor. Seizures in critical care. A guide to diagnosis and treatment. New York: Humana; 2010. p. 355-422.
47. Cook AM, Castle A, Green A, et al. Practice variations in the management of status epilepticus. Neurocrit Care. 2012;17:24-30.
48. Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345:631-7.
49. Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366:591-600.
50. •• Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134:2802-18. This is a comprehensive review of treatments available for SE.
51. Shorvon S, Ferlisi M. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135:2314-28.
52. McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005;366:205-10.
53. Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol. 2012;259:645-8.
54. Agarwal P, Kumar N, Chandra R, Gupta G, Antony AR, Garg N. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure. 2007;16:527-32.
55. Zelano J, Kumlien E. Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. Seizure. 2012;21:233-6.
56. Trinka E. What is the evidence to use new intravenous AEDs in status epilepticus? Epilepsia. 2011;52 Suppl 8:35-8.
57. Alvarez V, Januel JM, Burnand B, Rossetti AO. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia. 2011;52:1292-6.
58. Hofler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia. 2013
59. Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ. The use of topiramate in refractory status epilepticus. Neurology. 2003;60:332-4.
60. Hottinger A, Sutter R, Marsch S, Ruegg S. Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study. CNS Drugs. 2012;26:761-72.
61. Swisher CB, Doreswamy M, Gingrich KJ, Vredenburgh JJ, Kolls BJ. Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. Neurocrit Care. 2012;16:109-13.
62. Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia. 2002;43:146-53.
63. Krishnamurthy KB, Drislane FW. Depth of EEG suppression and outcome in barbiturate anesthetic treatment for refractory status epilepticus. Epilepsia. 1999;40:759-62.
64. Treiman DM. Convulsive status epilepticus. Curr Treat Options Neurol. 1999;1:359-69.
65. Krishnamurthy KB, Drislane FW. Relapse and survival after barbiturate anesthetic treatment of refractory status epilepticus. Epilepsia. 1996;37:863-7.
66. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol. 2005;62:1698-702.
67. Kramer AH. Early ketamine to treat refractory status epilepticus. Neurocrit Care. 2012;16:299-305.
68. Synowiec AS, Singh DS, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res. 2013. doi: 10.1016/j.eplepsyres.2013.01.007.
69. Schulze-Bonhage A, Kurthen M, Walger P, Elger CE. Pharmacorefractory status epilepticus due to low vitamin B6 levels during pregnancy. Epilepsia. 2004;45:81-4.
70. Kluger G, Blank R, Paul K, et al. Pyridoxine-dependent epilepsy: normal outcome in a patient with late diagnosis after prolonged status epilepticus causing cortical blindness. Neuropediatrics. 2008;39:276-9.
71. Minns AB, Ghafouri N, Clark RF. Isoniazid-induced status epilepticus in a pediatric patient after inadequate pyridoxine therapy. Pediatr Emerg Care. 2010;26:380-1.
72. Visser NA, Braun KP, Leijten FS, van Nieuwenhuizen O, Wokke JH, van den Bergh WM. Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations. J Neurol. 2011;258:218-22.
73. Iannetti P, Spalice A, Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia. 2005;46:967-9.
74. Iannetti P, Parisi P, Spalice A, Ruggieri M, Zara F. Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res. 2009;85:89-95.
75. Corry JJ, Dhar R, Murphy T, Diringer MN. Hypothermia for refractory status epilepticus. Neurocrit Care. 2008;9:189-97.
76. Rossetti AO. What is the value of hypothermia in acute neurologic diseases and status epilepticus? Epilepsia. 2011;52 Suppl 8:64-6.
77. Sierra-Marcos A, Maestro I, Rodriguez-Osorio X, et al. Successful outcome of episodes of status epilepticus after vagus nerve stimulation: a multicenter study. Eur J Neurol. 2012;19:1219-23.
78. Walker MC. The potential of brain stimulation in status epilepticus. Epilepsia. 2011;52 Suppl 8:61-3.
79. Lambrecq V, Villega F, Marchal C, et al. Refractory status epilepticus: electroconvulsive therapy as a possible therapeutic strategy. Seizure. 2012;21:661-4.
80. Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia. 1994;35:27-34.
81. DeLorenzo RJ, Towne AR, Pellock JM, Ko D. Status epilepticus in children, adults, and the elderly. Epilepsia. 1992;33 Suppl 4:S15-25.
82. Legriel S, Mourvillier B, Bele N, et al. Outcomes in 140 critically ill patients with status epilepticus. Intensive Care Med. 2008;34:476-80.
83. Rossetti AO, Oddo M, Liaudet L, Kaplan PW. Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology. 2009;72:744-9.
84. Hocker SE, Britton JW, Mandrekar JN, Wijdicks EF, Rabinstein AA. Predictors of outcome in refractory status epilepticus. JAMA Neurol. 2013;70:72-7.
85. Rossetti AO, Logroscino G, Bromfield EB. A clinical score for prognosis of status epilepticus in adults. Neurology. 2006;66:1736-8.
86. Rossetti AO, Logroscino G, Milligan TA, Michaelides C, Ruffieux C, Bromfield EB. Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol. 2008;255:1561-6.
87. Hesdorffer DC, Logroscino G, Cascino GD, Hauser WA. Recurrence of afebrile status epilepticus in a population-based study in Rochester, Minnesota. Neurology. 2007;69:73-8.
88. Varelas PN, Mirski MA. Seizures in the adult intensive care unit. J Neurosurg Anesthesiol. 2001;13:163-75.